Skip to main navigation Skip to search Skip to main content

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study

  • Tae Min Kim
  • , Nehal J. Lakhani
  • , Jacob Soumerai
  • , Manali Kamdar
  • , Justin F. Gainor
  • , Wells Messersmith
  • , Philip Fanning
  • , Shanhong Guan
  • , Feng Jin
  • , Alison Forgie
  • , Hong I. Wan
  • , Jaume Pons
  • , Sophia S. Randolph
  • , Won Seog Kim
  • Seoul National University
  • START Midwest
  • Harvard University
  • University of Colorado Anschutz Medical Campus
  • ALX Oncology Inc.
  • Sungkyunkwan University

Research output: Contribution to journal › Article › peer-review

10   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science